Key Points
- Atara Biotherapeutics CAO Yanina Grant-Huerta sold 2,414 shares on May 18 at an average price of $9.13, a transaction worth about $22,040. The sale reduced her stake by 4.64% and was made to cover tax withholding tied to vesting equity awards.
- The stock was modestly higher and the company remains small-cap, opening at $9.45 with a market cap of about $85.1 million. Over the past year, ATRA has traded between $3.92 and $19.15.
- Atara recently beat earnings expectations but missed revenue estimates, posting a loss of $0.29 per share versus the expected loss of $0.33, while revenue came in at $0.52 million compared with $2.90 million forecast. Analysts currently rate the stock a consensus Hold with a $9.50 price target.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) CAO Yanina Grant-Huerta sold 2,414 shares of the company's stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $9.13, for a total value of $22,039.82. Following the completion of the sale, the chief accounting officer owned 49,636 shares of the company's stock, valued at approximately $453,176.68. The trade was a 4.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Atara Biotherapeutics Stock Up 0.4%
NASDAQ ATRA opened at $9.45 on Thursday. The firm has a market cap of $85.14 million, a price-to-earnings ratio of -14.10 and a beta of -0.30. The business has a 50-day moving average price of $5.98 and a 200-day moving average price of $8.97. Atara Biotherapeutics, Inc. has a twelve month low of $3.92 and a twelve month high of $19.15.
Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 40.91%.The company had revenue of $0.52 million during the quarter, compared to analyst estimates of $2.90 million. Research analysts expect that Atara Biotherapeutics, Inc. will post 0.2 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
ATRA has been the topic of several recent research reports. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Atara Biotherapeutics in a research report on Friday, March 27th. Canaccord Genuity Group set a $13.00 price objective on Atara Biotherapeutics and gave the company a "buy" rating in a report on Friday, May 8th. Freedom Capital upgraded shares of Atara Biotherapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday. Finally, Wall Street Zen raised Atara Biotherapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $9.50.
View Our Latest Analysis on ATRA
Institutional Investors Weigh In On Atara Biotherapeutics
A number of large investors have recently made changes to their positions in ATRA. Raymond James Financial Inc. purchased a new stake in shares of Atara Biotherapeutics in the second quarter valued at approximately $31,000. Dimensional Fund Advisors LP purchased a new position in shares of Atara Biotherapeutics during the fourth quarter worth $181,000. Walleye Capital LLC purchased a new position in shares of Atara Biotherapeutics during the fourth quarter worth $220,000. Marshall Wace LLP purchased a new position in Atara Biotherapeutics in the second quarter valued at $327,000. Finally, Quadrature Capital Ltd boosted its holdings in Atara Biotherapeutics by 22.8% in the fourth quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company's stock valued at $368,000 after purchasing an additional 3,779 shares during the period. 70.90% of the stock is currently owned by hedge funds and other institutional investors.
Atara Biotherapeutics Company Profile
(
Get Free Report)
Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.
The company's lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
